Cheng‐Bo Han

1.2k total citations
76 papers, 864 citations indexed

About

Cheng‐Bo Han is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Cheng‐Bo Han has authored 76 papers receiving a total of 864 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pulmonary and Respiratory Medicine, 44 papers in Oncology and 17 papers in Cancer Research. Recurrent topics in Cheng‐Bo Han's work include Lung Cancer Treatments and Mutations (32 papers), Lung Cancer Research Studies (22 papers) and Lung Cancer Diagnosis and Treatment (19 papers). Cheng‐Bo Han is often cited by papers focused on Lung Cancer Treatments and Mutations (32 papers), Lung Cancer Research Studies (22 papers) and Lung Cancer Diagnosis and Treatment (19 papers). Cheng‐Bo Han collaborates with scholars based in China, United States and South Korea. Cheng‐Bo Han's co-authors include Jie‐Tao Ma, Shuling Zhang, Le‐Tian Huang, Huawei Zou, Li Sun, Wei Jing, Yijia Guo, Fan Li, Li Sun and Yanru Wang and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Cheng‐Bo Han

67 papers receiving 856 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cheng‐Bo Han China 17 471 381 270 190 112 76 864
Jie‐Tao Ma China 15 364 0.8× 311 0.8× 198 0.7× 153 0.8× 96 0.9× 43 677
Shakun Malik United States 18 455 1.0× 454 1.2× 316 1.2× 259 1.4× 78 0.7× 35 993
Angela Takano Singapore 16 425 0.9× 376 1.0× 230 0.9× 171 0.9× 97 0.9× 51 906
M. Ebert Germany 11 271 0.6× 328 0.9× 240 0.9× 189 1.0× 109 1.0× 17 732
Jianzhong Cao China 15 277 0.6× 253 0.7× 232 0.9× 150 0.8× 76 0.7× 58 620
Xianshu Gao China 18 477 1.0× 520 1.4× 314 1.2× 292 1.5× 100 0.9× 95 1.2k
Sayed M.S. Hashemi Netherlands 16 873 1.9× 560 1.5× 211 0.8× 142 0.7× 158 1.4× 57 1.1k
Eugenio Villa Italy 14 396 0.8× 676 1.8× 215 0.8× 157 0.8× 104 0.9× 20 973
Zhi-Qin Jiang United States 11 274 0.6× 564 1.5× 336 1.2× 205 1.1× 82 0.7× 12 881
K. Okubo Japan 18 721 1.5× 520 1.4× 213 0.8× 109 0.6× 67 0.6× 31 1.1k

Countries citing papers authored by Cheng‐Bo Han

Since Specialization
Citations

This map shows the geographic impact of Cheng‐Bo Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng‐Bo Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng‐Bo Han more than expected).

Fields of papers citing papers by Cheng‐Bo Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheng‐Bo Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng‐Bo Han. The network helps show where Cheng‐Bo Han may publish in the future.

Co-authorship network of co-authors of Cheng‐Bo Han

This figure shows the co-authorship network connecting the top 25 collaborators of Cheng‐Bo Han. A scholar is included among the top collaborators of Cheng‐Bo Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheng‐Bo Han. Cheng‐Bo Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yoon, Jihoon G., Cheng‐Bo Han, Shin Hye Noh, et al.. (2025). Digenic impairments of haploinsufficient genes in patients with craniosynostosis. JCI Insight. 10(4).
2.
Huang, Le‐Tian, et al.. (2024). First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. Scientific Reports. 14(1). 22901–22901. 1 indexed citations
3.
Sun, Li, et al.. (2024). Impact of Prophylactic Use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced NSCLC: A Cohort Study. JTO Clinical and Research Reports. 6(2). 100780–100780.
4.
Ma, Jie‐Tao, Jun S. Song, Xiaofang Yi, et al.. (2024). Enhanced T cell immune activity mediated by Drp1 promotes the efficacy of PD-1 inhibitors in treating lung cancer. Cancer Immunology Immunotherapy. 73(2). 40–40. 4 indexed citations
5.
6.
Zhang, Shuling, Li Sun, Le‐Tian Huang, et al.. (2024). Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells. Molecular Cancer. 23(1). 260–260. 23 indexed citations
7.
8.
Han, Cheng‐Bo, et al.. (2023). P2.09-22 Efficacy of Aumolertinib in EGFR T790M-negative or -unknown NSCLC with Brain Metastases Following Resistance to Prior EGFR-TKIs. Journal of Thoracic Oncology. 18(11). S341–S341. 2 indexed citations
9.
10.
Huang, Le‐Tian, Shuling Zhang, Cheng‐Bo Han, & Jie‐Tao Ma. (2022). Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer. Lung Cancer. 166. 9–16. 24 indexed citations
11.
Sun, Li, Yijia Guo, Jun Song, et al.. (2021). Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials. Frontiers in Oncology. 10. 586596–586596. 48 indexed citations
12.
Sun, Li, et al.. (2019). The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs. Translational Cancer Research. 8(5). 1834–1844. 1 indexed citations
13.
Huang, Le‐Tian, Jie‐Tao Ma, Shuling Zhang, et al.. (2019). Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report. Frontiers in Oncology. 9. 1453–1453. 15 indexed citations
14.
Ma, Jie‐Tao, Xiangyan Zhang, Rui Cao, et al.. (2019). Effects of Dynamin-related Protein 1 Regulated Mitochondrial Dynamic Changes on Invasion and Metastasis of Lung Cancer Cells. Journal of Cancer. 10(17). 4045–4053. 23 indexed citations
15.
Guo, Yijia, Rui Cao, Xiangyan Zhang, et al.. (2019). <p>Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer</p>. OncoTargets and Therapy. Volume 12. 10343–10360. 36 indexed citations
16.
17.
Zhang, Shuling, et al.. (2017). Benefits of postoperative thoracic radiotherapy for small cell lung cancer subdivided by lymph node stage: a systematic review and meta-analysis. Journal of Thoracic Disease. 9(5). 1257–1264. 5 indexed citations
18.
Han, Cheng‐Bo, Fan Li, Jie‐Tao Ma, & Huawei Zou. (2012). Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review. Cancer Investigation. 30(10). 741–747. 60 indexed citations
19.
Ma, Jie‐Tao, Cheng‐Bo Han, Wei Jing, et al.. (2012). Synergistic cytotoxic effects of recombinant human adenovirus p53 and radiation at various time points in A549 lung adenocarcinoma cells. Oncology Letters. 4(3). 529–533. 8 indexed citations
20.
Han, Cheng‐Bo. (2005). Quantitative analysis of tumor mitochondrial RNA using microarray. World Journal of Gastroenterology. 11(1). 36–36. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jie‐Tao Ma Breakdown of academic impact, for papers by Shakun Malik Breakdown of academic impact, for papers by Angela Takano Breakdown of academic impact, for papers by M. Ebert Breakdown of academic impact, for papers by Jianzhong Cao Breakdown of academic impact, for papers by Xianshu Gao Breakdown of academic impact, for papers by Sayed M.S. Hashemi Breakdown of academic impact, for papers by Eugenio Villa Breakdown of academic impact, for papers by Zhi-Qin Jiang Breakdown of academic impact, for papers by K. Okubo
Rankless by CCL
2026